15 May 2017Thermo Fisher Scientific to Acquire Patheon, a Leading Contract Development and Manufacturing Organization (CDMO)
-- Patheon Provides Entry into the Attractive, High-growth CDMO Market
-- Combination Significantly Strengthens Thermo Fisher's Unique Value Proposition for Pharmaceutical and Biotech Customers by Adding Highly Complementary Services
-- Creates Substantial Synergies and Positions Combined Company to Further Accelerate Growth
-- Expected to be Immediately and Significantly Accretive to Adjusted Earnings Per Share (EPS)Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, and Patheon N.V. (NYSE: PTHN), a leading global provider of high-quality drug development and delivery solutions to the pharmaceutical and biopharma sectors, today announced that their boards of directors have approved Thermo Fisher's acquisition of Patheon. Thermo Fisher will commence a tender offer to acquire all of the issued and outstanding shares of Patheon for $35.00 per share in cash. The transactionmore...
08 May 2017
Company Invests $26 million in Sterile PDS SuiteDURHAM, N.C.--(BUSINESS WIRE)--Patheon N.V (NYSE: PTHN), a leading global provider of high-quality drug development and delivery solutions to the pharmaceutical and biopharma sectors, announced that it has completed an expansion project at its Greenville, NC manufacturing site. The company invested approximately $26 million to update one of its sterile Pharmaceutical Development Services (PDS) suites and to build a state-of-the-art, fully integrated sterile PDS suitemore...
30 Mar 2017Patheon Achieved More Outsourced New Drug Approvals Than Any Other Provider According to 2017 PharmSource CMO Scorecard
Company “dominated” latest industry report with approximately 30 percent of all outsourced approvals, four times more than the nearest competitorDURHAM, N.C.--(BUSINESS WIRE)--Patheon N.V. (NYSE: PTHN), a leading global provider of high-quality drug development and delivery solutions to the pharmaceutical sector, has been cited once again as capturing the most outsourced new drug approvals (NDAs) in the US than any other contract manufacturing organization (CMO) in 2016. NDAs are authorized by the U.S. Food and Drug Administration (FDA). The annual 2017 PharmSource CMO Scorecard underscores the companymore...